The average one-year price target for Adaptive Biotechnologies (NasdaqGS:ADPT) has been revised to $19.53 / share. This is an increase of 16.52% from the prior estimate of $16.76 dated November 7, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $15.15 to a high of $23.10 / share. The average price target represents an increase of 38.48% from the latest reported closing price of $14.10 / share.
What is the Fund Sentiment?
There are 513 funds or institutions reporting positions in Adaptive Biotechnologies. This is an increase of 50 owner(s) or 10.80% in the last quarter. Average portfolio weight of all funds dedicated to ADPT is 0.23%, an increase of 24.34%. Total shares owned by institutions decreased in the last three months by 1.07% to 175,864K shares. 
The put/call ratio of ADPT is 0.25, indicating a bullish outlook.
What are Other Shareholders Doing?
Viking Global Investors holds 29,994K shares representing 19.65% ownership of the company. No change in the last quarter.
Ameriprise Financial holds 5,972K shares representing 3.91% ownership of the company. In its prior filing, the firm reported owning 3,240K shares , representing an increase of 45.74%. The firm decreased its portfolio allocation in ADPT by 59.52% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 4,489K shares representing 2.94% ownership of the company. In its prior filing, the firm reported owning 4,488K shares , representing an increase of 0.01%. The firm increased its portfolio allocation in ADPT by 39.91% over the last quarter.
IWM - iShares Russell 2000 ETF holds 3,707K shares representing 2.43% ownership of the company. In its prior filing, the firm reported owning 3,078K shares , representing an increase of 16.96%. The firm increased its portfolio allocation in ADPT by 90.65% over the last quarter.
Sumitomo Mitsui Trust Holdings holds 3,651K shares representing 2.39% ownership of the company. In its prior filing, the firm reported owning 4,300K shares , representing a decrease of 17.78%. The firm increased its portfolio allocation in ADPT by 0.68% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
